Acute Stroke Care — Opportunities for Limiting Brain Damage

Baum HM Robins M. National survey of stroke: Survival and prevalence. Stroke 1981; 12(Supp 1): 59–68.

Bamford J Sandercock P Dennis M A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project 1981–1986: 1 Methodology, demography and incident cases of first ever stroke. J Neurol, Neurosurg Psychiatry 1988; 51:1373–1380.

Adelman MS . National survey of stroke: Economic impact. Stroke 1981; 12(Suppl 1):69–78.

Wolf PA D'Agostino RB Belanger AJ Probability of stroke: A risk profile from the Framingham study. Stroke 1991; 22: 312–318.

Melville ID Renfrew S. The prognosis of survival from cerebrovascular accidents. J Neurol Neurosurg Psychiatry 1961; 24: 346–349.

Thomson JA . Strokes in an acute medical unit. Health Bull 1971; 29: 113–114.

Lowe GDO Jaap AJ Forbes CD . Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983; i: 784–786.

Dale S. Stroke 1988; Office of Health Economics, No 89, London.

Aho K Harmsen P Hatano S Marquardsen J Cerebrovascular disease in the community: Results of a WHO Collaborative Study. Bull of the WHO 1980; 58: 113–130.

Whishnant JP . The decline of stroke. Stroke 1984; 15: 160–168.

Shinton R Beevers G. Meta analysis of relation between cigarette smoking and stroke. Br Med J 1989; 298: 789–794.

Collins R Peto R MacMahon S Blood pressure, stroke and coronary heart disease, Part II: Effects of short term reductions in blood pressure — And overview of the unconfounded randomised drug trials in an epidemiological context. Lancet 1990; 335: 827–838.

Cerebral Embolism Task Force: Cardiogenic brain embolism, Arch Neurol 1986; 43: 71–84.

Sandercock PAG Warlow CP Jones LN Predisposing factors for cerebral infarction: The Oxfordshire community stroke project. Br Med J 1989; 298: 75–80.

Allen CMC . Predicting outcome after acute stroke: Role of computed tomography. Lancet 1985; ii: 464–465.

Astrup J Siesjö BK Symon L. The state of penumbra in the ischaemic brain: Viable and lethal threshold in cerebral ischaemia. Stroke 1981; 12: 723–725.

Gruppo Italiano per lo Studio della Streptokinasi nell' Infarto Miocardio (GISSI). Efectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 297–301.

Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349–360.

The Thrombolysis in Myocardial Infarction (TIMI) Study Group. Comparison of invasive and conservative strategies after treatment with intravenous plasminogen activator in acute myocardial infarction. New Engl J Med 1989; 320: 618–627.

Petch MC . Dangers of thrombolysis (Editorial). Br Med J 1990; 300: 483.

The r-tPA/Acute Stroke Study Group. An open safety/efficacy trial of r-tPA in acute thromboembolic stroke: Final report. Stroke 1991; 22: 153 (Abstract).

Brott Haley C Levy D Safety and potential efficacy of tissue plasminogen activator (t-PA) for stroke. Stroke 1990; 181 (Abstract).

McCord JM . Oxygen-derived free radicals in postischaemic tissue injury. New Engl J Med 1985; 312: 159–163.

Uyama O Shiratsuki N Matsuyama T Nakanishi T Matsumoto Y Yamada T Protective effects of recombinant human superoxide dismutase on reperfusion injury of gerbil brain. Stroke 1990; 21: (Suppl 1): 1–32.

Hall ED Pazara KE Braughler JM . 21-aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischaemia in gerbils. Stroke 1988; 19: 997–1002.

Rothman SM Olney JW . Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986; 19: 105–111.

Steinberg GK Lo EH Kunis DM Grant G. Dextromethorphan prevents post ischemic increase in cerebral blood flow and protects against cerebral injury following focal cerebral ischemia. Stroke 1991; 22: 141(Abstract).

Johnson RL Koerner JF . Excitatory amino acid neurotransmission. J Med Chem 1988; 31: 2057–2066.

Gill R Foster AC Woodruff GN . Systemic administration of MK-801 protects aganst ischaemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 1987; 7: 3343–3349.

McDonald JW Silverstein FS Johnston MV . MK-801 protects the neonatal brain from hypoxic-ischaemic damage. Eur J Pharmacol 1987; 140: 359–361.

Albers GW Goldberg MP Choi DW . N-methyl-D-asparate antagonists; ready for clinical trial in brain ischemia? Ann Neurol 1989; 25: 398–403.

Greenberg JH Uematsu D Araki N Cytosolic free calcium during focal cerebral ischaemia and the effects of nimodipine on calcium and histologic damage. Stroke 1990; (Suppl): 72–77.

Gelmers HJ Forter K de Weerdt CJ A controlled trial of nimodipine in acute ischaemic stroke. New Engl J Med 1988; 318: 203–207.

Tomberg T Magi M. Effect of calcium antagonists on cerebral blood flow in the acute stage of cerebral infarction. J Neurol 1990; 237: 138.

Trust Study Group. Randomised double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet 1990; 336: 1205–1209.

Martinez-Villa E Guillen F Vuillaneuva JA Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 1990; 21: 1023–1028.

Norris JW Hachinski VC . High dose steroid treatment in cerebral infarction. Br Med J 1986; 292: 21–23.

Sapolsky RM Pulsinelli WA . Glucocorticoids potentiate ischemic injury to neurons; therapeutic implications. Science 1985; 229: 1397–1400.

Italian Acute Stroke Study Group. Haemodilution in acute stroke: Results of the Italian haemodilution trial. Lancet 1988; i: 318–321.

Shaper AG Phillips AN Pocock SJ Risk factors for stroke in middle-aged British men. Br Med J 1991; 302: 1111–1115.

Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: Risk factors and the value of treatment. Br Med J 1988; 296: 1565–1570.

Donnan GA McNeil JJ Adena MA Smoking as a risk factor for cerebral ischaemia. Lancet 1989; ii: 643–647.

Antiplatelet Triallists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–331.